Intake sets the deficit; how you spend it decides what else you lose
Once you have decided the fat is worth losing — a separate question, settled in Body Fat — the methods stop being a contest between diets and start being a contest between deficits. Every method works by the same lever: spend more energy than you take in. Food intake is where that deficit is won or lost, because the body quietly claws back a large share of the calories that exercise burns.
So the first ranking is blunt. The drug takes the most weight off and is the only method with a proven reduction in a hard outcome. Diet composition barely matters for how much comes off, once calories match. Exercise earns its place through where the fat leaves and what it protects, not through the number on the scale. And the whole field shares one binding constraint that no method escapes: losing the weight is the easy part, and keeping it off is the part that mostly fails.
Numbers here are population averages for adults with overweight or obesity; a person’s own result varies widely. And a caution that runs through everything below — this fabric grades how well the evidence hangs together, not whether following it makes you better off. That loop stays open.
The body defends the deficit, and defends it harder the heavier you are
Exercise does not subtract cleanly from the energy balance. People eat more, move less the rest of the day, or both, so the measured energy deficit is smaller than the calories burned in the session. Riou’s review put the average compensation near 18% early on, but with enormous spread (SD around ±93%), and found it climbing toward roughly 84% of the exercise energy by about 80 weeks (Riou et al., 2015).
Careau’s doubly-labelled-water analysis across 1,754 adults sharpened the pattern: compensation averaged about 28%, and — the decision-relevant part — it rose with body fatness, from roughly 27.7% at the leanest end of the BMI distribution to 49.2% at the heaviest (Careau et al., 2021). The person with the most fat to lose gets the least deficit back per unit of exercise. That is why intake, not activity, anchors how much weight moves — and why exercise is prescribed below for what it does to the depot and to muscle, not for the calories it appears to burn -> Exercise Energy Compensation.
How you create the deficit changes where the fat comes off
Two deficits of equal size do not empty the same fat. Recchia’s meta-analysis compared exercise-widened against diet-created deficits for visceral fat specifically. Per unit of energy, exercise showed a dose-response on visceral adiposity (−0.15 SD per 1000 kcal/week, 95% CI −0.23 to −0.07) while caloric restriction did not (0.03, −0.12 to 0.18, p=0.64); with the size of the deficit held equal, exercise was the more effective at shifting the visceral depot (standardized effect −0.18, 95% CI −0.33 to −0.04, p=0.012) (Recchia et al., 2023).
The catch, kept honest: for total fat and waist circumference the raw comparison favours diet (waist −4.67 cm on restriction vs −3.15 cm on exercise) (Recchia et al., 2023), because people restrict harder than they exercise. Both bodies of evidence are moderate GRADE, the effects are in standardized units rather than cm² of fat, and the compensation problem above means the exercise deficit is the hardest to actually bank. The signal worth carrying is directional: exercise buys a visceral-specific benefit that diet alone does not -> Exercise vs Caloric Restriction for Visceral Fat.
Does losing faster change what you lose? The rate-of-loss question — crash versus gradual — resolves as a minor knob. Faster loss from a steeper deficit takes off more total weight in the window, and the worry is that it strips more muscle, but the magnitude of any extra lean loss attributable to speed has no gold meta-analysis behind it (a named gap). The durability evidence below shows that the rate at which weight comes off predicts regain far less than whether the deficit is sustained at all.
You lose lean mass too — the ratio improves while the kilograms fall
Any large weight loss takes muscle with it, and the honest framing holds two facts at once. As a proportion of body weight, lean mass goes up on a GLP-1 drug — Laverde’s meta-analysis found lean mass as a share of total weight rising +1.81% (95% CI 1.10 to 2.52). In absolute kilograms it falls: −1.74 kg (95% CI −3.04 to −0.45) across the class, and −5.44 kg (about −9.9%) on semaglutide (Laverde et al., 2026). Roughly 30% of the weight lost on these drugs is lean tissue, a fraction comparable to bariatric surgery, and it varies by agent (semaglutide running higher than liraglutide). Laverde’s own reading is that this is not a reason to withhold the drug: «Our results suggest that lean mass loss should not be considered a limitation for the use of these drugs in patients with obesity» (Laverde et al., 2026) — though the same conclusion adds that treatment should be paired with nutrition and exercise.
Nong’s network meta-analysis puts numbers on the spread: tirzepatide −8.3%, subcutaneous semaglutide −5.8% of lean mass (Nong et al., 2026) -> GLP-1 and Lean Mass.
Whether that lean loss matters is where surrogate and outcome part company. Low muscle mass tracks mortality — de Santana’s meta-analysis found lower appendicular skeletal muscle mass index associated with death (SMD −0.18, 95% CI −0.23 to −0.12) — but the grip-strength moderator was non-significant and underpowered, and the association is predictive, not proven causal (de Santana et al., 2021).
The clinical instruments say the same: EWGSOP2 moved strength ahead of mass because «strength is better than mass in predicting adverse outcomes» (Cruz-Jentoft et al., 2018), and its cut-offs (grip <27 kg men, <16 kg women) are set against healthy young reference values, not validated against outcomes. No trial has shown that preserving muscle during weight loss changes any hard outcome — that is a type-G gap, and the GLP-1 trials measured no strength or function at all -> Low Muscle Mass and Mortality, Sarcopenia Definition and Diagnosis, Surrogate Outcomes.
The defence against lean loss is training, not protein
Resistance training is the lever with the direct evidence. Adding it plus protein raised strength (+2.49 kg one-rep-max, 95% CI 0.64 to 4.33) and fat-free mass (+0.30 kg, 95% CI 0.09 to 0.52) in Morton’s meta-analysis (Morton et al., 2017).
Protein is a modest adjunct with a soft target: Morton found the resistance-training benefit of added protein plateaus, but the break-point was not statistically significant (p=0.079), so the widely-quoted ~1.6 g/kg is a region, not a settled number, and no study pinned a hard knee — the exact figure and its wide interval live on Protein and Resistance Training for Muscle and Strength (Morton et al., 2017). A separate meta-analysis using a different quantity put its knee near 1.3 g/kg (Tagawa et al., 2020). In an energy deficit the requirement to retain fat-free mass is likely higher — Refalo’s review points toward roughly 1.9 g/kg of body mass, though that figure is exploratory (Refalo et al., 2025). The order of operations is what matters: train against resistance, eat adequate protein in a defensible range, and treat the exact gram as fine-tuning -> Protein and Resistance Training for Muscle and Strength.
What each method actually moves
The drug moves the most weight, and once, moves an outcome. Semaglutide took off about 12.4 percentage points of body weight in STEP-1 (95% CI −13.4 to −11.5), with half of participants losing at least 15% (Wilding et al., 2021). Tirzepatide went further in SURMOUNT-1 — placebo-adjusted loss of 11.9 to 17.8 points by dose, and 57% losing at least 20% at the top dose (Jastreboff et al., 2022).
The result that separates the class from every diet is the SELECT trial: in adults with established cardiovascular disease and obesity, semaglutide cut major adverse cardiovascular events, «hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001» (Lincoff et al., 2023). Read that as it was earned: an absolute risk reduction of about 1.5 points over 3.3 years, roughly one event prevented per 67 people treated, in a secondary-prevention population. The trial’s own statistical hierarchy stopped at cardiovascular death (HR 0.85, P=0.07, not significant), so the all-cause mortality figure (0.81) and the components below it are point estimates the trial did not formally confirm. Whether the drug prevents events in lower-risk primary prevention is untested.
Nong’s network meta-analysis is consistent: subcutaneous semaglutide was «the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93)» (Nong et al., 2026); tirzepatide, despite the larger weight loss, reaches only heart-failure signals so far, and its hard-outcome trial is a gap -> Semaglutide for Cardiovascular Risk in Obesity, Comparing Obesity Drugs, GLP-1 Drugs.
Total diet replacement is the strongest lifestyle lever, and for a specific person it can undo a disease. A structured 825-853 kcal/day formula diet drove type-2-diabetes remission in DiRECT — 46% of the intervention group versus 4% of controls (odds ratio 19.7, 95% CI 7.8 to 49.8) — and remission tracked how much weight came off, from 0% in those who gained to 86% in those losing 15 kg or more (Lean et al., 2018). Churuangsuk’s umbrella review makes total diet replacement its single GRADE-HIGH cell, with a median 54% remission (Churuangsuk et al., 2021). The mechanism is the calorie deficit and the weight lost, not the 59%-carbohydrate composition of the formula -> Total Diet Replacement and Type 2 Diabetes Remission, Type 2 Diabetes.
Carbohydrate restriction buys an early edge that fades. For people with type 2 diabetes, a low-carbohydrate diet (<26% of energy, or <130 g/day) raised remission at 6 months (risk difference 0.32, 95% CI 0.17 to 0.47), but by 12 months the medication-free difference was gone (−0.04, 95% CI −0.16 to 0.09) (Goldenberg et al., 2021). The early gain rides on weight and on the definitional freedom to count remission while medications are still deprescribed -> Carbohydrate Restriction and Type 2 Diabetes Remission.
Once calories are fixed, the macronutrient split barely changes the fat lost. In tightly controlled feeding studies pooled by Hall (32 studies, 563 subjects), lower-fat diets produced marginally more fat loss than lower-carbohydrate ones at matched calories — greater energy expenditure by 26 kcal/day and fat loss by 16 grams/day — the opposite direction the carbohydrate-insulin model predicts, and small enough to call a wash (Hall & Guo, 2017). The head-to-head outpatient trial agrees: DIETFITS found −5.3 kg on low-fat versus −6.0 kg on low-carbohydrate, a 0.7 kg difference (95% CI −0.2 to 1.6), with no benefit from matching the diet to insulin secretion or genotype [@gardner2018].
Where composition does bite is intake itself — the same investigator’s inpatient trial found people ate 508 kcal/day more on an ultra-processed diet than a matched unprocessed one, eating freely (Hall et al., 2019). So the diet that works is the one that holds the deficit, and low-carbohydrate diets move LDL cholesterol least among the popular patterns, a minor safety point rather than a weight one (Ge et al., 2020) -> What Drives Fat Gain - Energy Balance vs the Carbohydrate-Insulin Model.
Keeping it off is the part that fails
The trajectory is remarkably consistent across methods. Franz’s synthesis of one-year-plus trials found weight bottoming out around 5 to 8.5 kg (5-9%) by about 6 months, then drifting back — very-low-energy diets peaked highest (17.9 kg, 16%) and regained most, settling near 5.6 kg by 3 years, while diet-alone groups held about 3 kg at 4 years, and no group returned to baseline (Franz et al., 2007). The body enforces this. After an 8-week very-low-energy diet that lost 13.5 kg, Sumithran’s participants still had leptin 35.5% below baseline and elevated hunger hormones a full year later, with the drive to eat still switched on (Sumithran et al., 2011) — a defended set-point, not a failure of willpower -> Weight-Loss Maintenance and Metabolic Adaptation.
The drug is not exempt; it is dependent. Stopping semaglutide in the STEP-1 extension gave back about two-thirds of the lost weight within a year (11.6 points) (Wilding et al., 2022), and the network evidence puts off-drug regain near 0.4 kg/month, back toward baseline within roughly 1.7 years (Nong et al., 2026). This reframes the drug as a chronic therapy for a chronic condition, like a blood-pressure pill, rather than a course of treatment. The single most decision-relevant fact in this whole cut: adherence is not a footnote to the effect, it is most of the effect — a smaller deficit sustained beats a larger one abandoned.
Matching the lever to the person
The ranking is stratum-dependent, and an effective drug changes the size of the lifestyle rock rather than removing it. For someone with type 2 diabetes and substantial weight to lose, total diet replacement can reach remission and is the strongest lifestyle option on the table. For someone at high cardiovascular risk with obesity, the GLP-1 class is the only method with a hard-outcome trial behind it, and its rank is net of its own costs — lifelong dependency, cost, gastrointestinal side-effects, and the fact that it manages weight without fixing whatever drives it.
That last point is why the drug does not retire exercise: a single-channel drug does not substitute for a pleiotropic lever, so resistance training keeps its place for muscle and function, and aerobic exercise keeps its place for the visceral depot, even for a person on semaglutide. For a younger, well-muscled person with modest fat to lose, the lean-mass worry is small and the deficit plus training is enough. For an older or sarcopenia-risk person, the lean-mass loss on a steep deficit is the real hazard, and training becomes non-negotiable rather than optional -> Baseline Risk and the Relative-Absolute Split.
How to think about your own choice
Pick the method you can hold, because durability is where nearly every attempt fails. Anchor the deficit at intake; use exercise for the visceral fat and the muscle it protects, not for the calories it seems to burn. If you are losing meaningful weight, train against resistance and eat protein in a defensible range (somewhere around 1.6 to 1.9 g/kg while dieting) to keep the loss weighted toward fat. Judge a drug against the realistic alternative you would actually sustain, and against its own costs and its dependency — and know that stopping it hands most of the weight back. The scale is the easy win; the maintenance plan is the decision. What none of this can tell you is whether your particular choice leaves you better off years from now — the evidence here is coherent and source-checked, but the outcome loop is open.
Evidence box
Question ’For an adult who has decided to reduce body fat: how do the available methods — diet composition, calorie restriction, exercise, total diet replacement, and pharmacotherapy (the GLP-1 class) — compare on how much weight comes off, what else is lost (lean mass, function), whether the loss reaches a hard outcome or only a surrogate, and how durably it lasts; and does the rate of loss or the source of the deficit (diet-created vs exercise-widened) change body composition over and above the amount lost?‘ Evidence included 23 sources — 8 gold, 15 high Overall certainty Medium (see Rating Certainty of Evidence) Source-selection note All sources are gold or high tier. Last updated 2026-09-09 · Independently reviewed: No · Full edit history